Urinary Incontinence Therapeutics Global Analysis & Forecast to 2025 Urinary Incontinence Therapeutics Market - Global | Page 2

includes, but is not limited to beta-3 adrenergic agonists, topical estrogens, and
serotonin – nor-epinephrine reuptake inhibitors. Recent advances in these
therapeutic classes include the marketing of M3 specific anticholinergic drugs,
which have low side effects due to increased bladder receptor sensitivity. Based on
distribution channels, the global urinary incontinence therapeutics market has been
segmented into hospital pharmacy stores, retail pharmacy stores, and online
pharmacies.
The major challenge in the global urinary incontinence therapeutics market is the
efficacy of these medications along with reducing their adverse effects. Recent new
pharmacogenic advances in introduction of transdermal medications with better
efficacy and tolerability than the conventional oral therapeutics serves as a major
opportunity to the market. Counseling efforts from manufacturers with the help of
various social organizations or NGOs is seen as a rising trend in the global urinary
incontinence therapeutics market, which in turn is expected to increase therapeutic
treatment adoption.
In terms of region, the global urinary incontinence therapeutics market has been
divided into five regions: North America, Europe, Asia Pacific, Latin America, and
Middle East & Africa. Asia Pacific is projected to experience exponential growth
owing to increasing geriatric population, and increasing awareness about the
treatment as well as diagnosis of overactive bladder conditions. North America is
estimated to dominate the global urinary incontinence therapeutics market due to
new and technologically advanced products introduced in the market and increasing
specialty research initiatives in the field of urinary disorders. The global urinary
incontinence therapeutics market is anticipated to experience high growth in
pharma – emerging regions as several local manufacturers have a robust pipeline in
the field of urinary incontinence research, due to the increasing demand for
economic and efficient medications.
Key players in the global urinary incontinence therapeutics market are Johnson &
Johnson (Janssen Global Services, LLC), Pfizer Inc., Astellas Pharma, Inc., ALLERGAN,
Abbott, Sanofi, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cytori
Therapeutics Inc., and Atlantic Therapeutics among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth
qualitative insights, historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven research
methodologies and assumptions. By doing so, the research report serves as a
repository of analysis and information for every facet of the market, including but
not limited to: Regional markets, technology, types, and applications.
Get accurate market forecast and analysis on the Gadolinium-based
Contrast Agent market. Request a sample to stay abreast on the key
trends impacting this market.
http://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=22883